Results 261 to 270 of about 69,436 (336)
Cold-Induced Urticarias with Familial Background: Clinical Spectrum, Pathogenesis, and Diagnostic Challenges. [PDF]
Zhou N, Zhi Y.
europepmc +1 more source
ABSTRACT Daridorexant, a dual orexin receptor antagonist, is approved for the treatment of insomnia disorder in adults. Approximately 30%–35% of patients with insomnia disorder also have obstructive sleep apnoea (OSA) of any severity. It is unclear whether sleep medications provide safe and effective treatment for insomnia in these patients.
Christopher J. Lettieri +8 more
wiley +1 more source
Shiitake mushroom-induced flagellate erythema. [PDF]
Karponis D, Venables ZC.
europepmc +1 more source
Management of Insomnia Complaints by Non‐Sleep Specialist Physicians: A French DELPHI Consensus
ABSTRACT Insomnia is the most prevalent sleep disorder and a major public health concern, affecting chronically up to 19% of the adult population in France. Despite its significant impact on quality of life, mental health, and cardiometabolic disease, insomnia disorder remains underdiagnosed and inadequately managed.
Pierre‐Alexis Geoffroy +6 more
wiley +1 more source
Comparative study on severity and preventive behaviors of Japanese cedar pollen allergy during pollen scattering season: Single-center analysis. [PDF]
Tai T +9 more
europepmc +1 more source
Our study showed that, in healthy controls, acute administration of linaclotide increased the total number of long‐distance propagating and the pre‐prandial pancolonic pressurizations. Further studies need to address whether the observed effects are directly or indirectly mediated by the mechanism of action of this useful medication to treat chronic ...
Christian Lambiase +7 more
wiley +1 more source
Response to comments on "Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab". [PDF]
Hayama K, Ito-Watanabe M, Fujita H.
europepmc +1 more source
Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review
ABSTRACT We report an 11‐month‐old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off‐label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of ...
Janis Chang +3 more
wiley +1 more source

